PURPOSE: Congenital diaphragmatic hernia (CDH) is associated with pulmonary hypertension which is often difficult to manage, and a significant cause of morbidity and mortality. In this study, we have used a rabbit model of CDH to evaluate the effects of BAY 60-2770 on the in vitro reactivity of left pulmonary artery. METHODS: CDH was performed in New Zealand rabbit fetuses (n = 10 per group) and compared to controls. Measurements of body, total and left lung weights (BW, TLW, LLW) were done. Pulmonary artery rings were pre-contracted with phenylephrine (10 μM), after which cumulative concentration-response curves to glyceryl trinitrate (GTN; NO donor), tadalafil (PDE5 inhibitor) and BAY 60-2770 (sGC activator) were obtained as well as the levels of NO (NO3/NO2). RESULTS: LLW, TLW and LBR were decreased in CDH (p < 0.05). In left pulmonary artery, the potency (pEC50) for GTN was markedly lower in CDH (8.25 ± 0.02 versus 9.27 ± 0.03; p < 0.01). In contrast, the potency for BAY 60-2770 was markedly greater in CDH (11.7 ± 0.03 versus 10.5 ± 0.06; p < 0.01). The NO2/NO3 levels were 62 % higher in CDH (p < 0.05). CONCLUSION: BAY 60-2770 exhibits a greater potency to relax the pulmonary artery in CDH, indicating a potential use for pulmonary hypertension in this disease.
PURPOSE:Congenital diaphragmatic hernia (CDH) is associated with pulmonary hypertension which is often difficult to manage, and a significant cause of morbidity and mortality. In this study, we have used a rabbit model of CDH to evaluate the effects of BAY 60-2770 on the in vitro reactivity of left pulmonary artery. METHODS: CDH was performed in New Zealand rabbit fetuses (n = 10 per group) and compared to controls. Measurements of body, total and left lung weights (BW, TLW, LLW) were done. Pulmonary artery rings were pre-contracted with phenylephrine (10 μM), after which cumulative concentration-response curves to glyceryl trinitrate (GTN; NO donor), tadalafil (PDE5 inhibitor) and BAY 60-2770 (sGC activator) were obtained as well as the levels of NO (NO3/NO2). RESULTS: LLW, TLW and LBR were decreased in CDH (p < 0.05). In left pulmonary artery, the potency (pEC50) for GTN was markedly lower in CDH (8.25 ± 0.02 versus 9.27 ± 0.03; p < 0.01). In contrast, the potency for BAY 60-2770 was markedly greater in CDH (11.7 ± 0.03 versus 10.5 ± 0.06; p < 0.01). The NO2/NO3 levels were 62 % higher in CDH (p < 0.05). CONCLUSION:BAY 60-2770 exhibits a greater potency to relax the pulmonary artery in CDH, indicating a potential use for pulmonary hypertension in this disease.
Authors: Raul A Cortes; Roberta L Keller; Tiffany Townsend; Michael R Harrison; Diana L Farmer; Hanmin Lee; Robert E Piecuch; Carol H Leonard; Maria Hetherton; Robin Bisgaard; Kerilyn K Nobuhara Journal: J Pediatr Surg Date: 2005-01 Impact factor: 2.545
Authors: Johannes-Peter Stasch; Peter M Schmidt; Pavel I Nedvetsky; Tatiana Y Nedvetskaya; Arun Kumar H S; Sabine Meurer; Martin Deile; Ashraf Taye; Andreas Knorr; Harald Lapp; Helmut Müller; Yagmur Turgay; Christiane Rothkegel; Adrian Tersteegen; Barbara Kemp-Harper; Werner Müller-Esterl; Harald H H W Schmidt Journal: J Clin Invest Date: 2006-09 Impact factor: 14.808
Authors: Stefany B A Cau; Carlos A Dias-Junior; Marcelo F Montenegro; Gilberto de Nucci; Edson Antunes; Jose E Tanus-Santos Journal: Eur J Pharmacol Date: 2007-11-24 Impact factor: 4.432
Authors: Marc Chester; Pierre Tourneux; Greg Seedorf; Theresa R Grover; Jason Gien; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-05-22 Impact factor: 5.464
Authors: Aline Vuckovic; Susanne Herber-Jonat; Andreas W Flemmer; Brigitte Strizek; Alexander C Engels; Jacques C Jani Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-02-12 Impact factor: 5.464